Oralair

Allergen Extract From Pollen Of Dactylis Glomerata, Anthoxanthum Odoratum, Lolium Perenne, Poa Prate, the active ingredient in Oralair, is an allergen immunotherapy presented as a sublingual tablet for oral administration. It is used to treat grass‑pollen‑induced allergic rhinitis in patients with confirmed sensitivity.

GNH USA supplies Oralair as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and research institutions worldwide.

Oralair is an allergen immunotherapy that targets grass‑pollen‑related allergic disease.

- Grass pollen allergic rhinitis: reduces nasal congestion, sneezing and itching during the grass season. - Seasonal allergic rhinoconjunctivitis (grass): improves overall symptom control and quality of life. - Grass‑induced allergic asthma (adjunct): may lessen asthma exacerbations linked to grass exposure.

Adverse reactions are generally localized to the oral cavity but can range from mild to severe.

Common Side Effects: - Oral itching or tingling: mild discomfort in the mouth after dosing. - Throat irritation: transient soreness or scratchy sensation. - Ear pruritus: itching in the ears or around the jaw. - Mild gastrointestinal upset: nausea or mild stomach discomfort. - Local swelling of the tongue or lips: transient and self‑limiting.

Serious or Rare Side Effects: - Anaphylaxis: rapid onset of systemic allergic reaction requiring emergency care. - Severe systemic allergic reaction: widespread urticaria, angioedema, or respiratory distress. - Asthma exacerbation: worsening of underlying asthma symptoms. - Severe oral edema: pronounced swelling that interferes with breathing or swallowing. - Cardiovascular collapse: rare but life‑threatening drop in blood pressure.

Oralair should be used with careful patient selection and monitoring.

- Contraindication: severe uncontrolled asthma: avoid use until asthma is stable. - Pregnancy: limited data, use only if potential benefit outweighs risk. - Breastfeeding: no specific studies, consider risk‑benefit before prescribing. - Monitoring: observe patients for at least 30 minutes after first dose for systemic reactions. - Drug interactions: inform patients about possible interactions with immunosuppressants. - Storage: Store at ambient temperature below 25°C: keep in original container, protect from moisture and direct sunlight.

Oralair may interact with other agents that affect immune response or mask allergic symptoms.

Major Interactions (Avoid): - Beta‑blockers: may blunt response to emergency epinephrine during anaphylaxis. - Immunosuppressive therapy (e.g., high‑dose steroids, chemotherapy): may reduce efficacy of immunotherapy.

Moderate Interactions (Monitor Closely): - Antihistamines: can mask early local reactions, making monitoring harder. - Systemic corticosteroids: may alter immune modulation during treatment. - Omalizumab (anti‑IgE): may affect the clinical response to allergen extracts. - Live vaccines: schedule administration to avoid overlapping immune activation.